ArticleEmerging infectious diseases2025
Progression from Candida auris Colonization Screening to Clinical Case Status, United States, 2016-2023.
Article in Emerging infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Methods for skin load reduction of Candida auris: a systematic review.Antimicrobial resistance and infection control · 2026Pooled it
- Multicenter performance evaluation of the SimplexaJournal of clinical microbiology · 2026Article
- Surveillance for Candida auris - United States, 2022-2024.Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002) · 2026Article
- Diabetes and Immunosuppression Drive Distinct Patterns ofbioRxiv : the preprint server for biology · 2026Article
- Yeast identification, antifungal susceptibility testing, andJournal of clinical microbiology · 2026Article
- Risk Factors Associated With Progression to Clinical Candida auris Infection Among Adults With Previous Colonization-Florida, 2019-2023.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Review
- Article
- Breaking the Chain of Infection: A Systematic Review of Environmental Decontamination ofJournal of fungi (Basel, Switzerland) · 2026Review
- Review
- EnhancedAntimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Prevalence, pattern of disease and antimicrobial susceptibility ofSouthern African journal of infectious diseases · 2026Article
- Next-generation Candida albicans vaccine VXV-01 containing recombinant Als3p and Hyr1p antigens for invasive Candida infections.Scientific reports · 2025Article
- Progression from Candida (Candidozyma) auris colonization to bloodstream infection, New York State (NYS) and Chicago.American journal of infection control · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During 2016-2023, among 21,195 US patients who tested positive for Candida auris colonization, 6.9% were subsequently found to have a positive clinical specimen (2.8% from blood). Strategies are needed to prevent invasive C. auris infections among patients with colonization (e.g., through patient decolonization).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.